Munich Cancer Registry



- Baseline statistics
- Selection Matrix
- Homepage
- Deutsch

Munich Cancer Registry at Munich Cancer Center Marchioninistr. 15 Munich, 81377 Germany

http://www.tumorregister-muenchen.de/en

Cancer statistics: Survival

GIST: Gastroint. stromal tumor

Year of diagnosis	1988-2013
Patients	715
Diseases	716
Cases evaluated	264
Creation date	05/13/2015
Export date	12/30/2014
Population	4.64 m



http://www.tumorregister-muenchen.de/en/facts/surv/surv_hGISTE.pdf




Figure 1a. Relative survival of patients with gastroint. stromal tumor by period of diagnosis. Included in the evaluation are 259 cases diagnosed between 1998 and 2013.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided populationbased statistics since 1988, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

Period of diagnosis											
	1998-	2006	200)7+							
	n=1	60	n=99								
Years	obs. %	rel. %	obs. %	rel. %							
0	100.0	100.0	100.0	100.0							
1	83.1	85.1	88.8	90.9							
2	75.8	78.6	86.3	89.3							
3	71.4	76.4	83.5	88.3							
4	65.8	71.2	78.5	84.7							
5	58.5	64.9	75.1	80.9							

Table 1b. Observed (obs.) and relative (rel.) survival of patients with gastroint. stromal tumor by period of diagnosis for period 1998-2013 (N=259).




Figure 2a. Survival of patients with gastroint. stromal tumor by gender. Included in the evaluation are 259 cases diagnosed between 1998 and 2013.

	C	Gender	r		
	Ma	ale	Female		
	n=1				
Years	obs. %	rel. %	obs. %	rel. %	
0	100.0	100.0	100.0	100.0	
1	86.8	89.0	83.7	85.3	
2	77.5	81.5	81.9	84.3	
3	74.8	79.8	76.8	80.2	
4	71.0	78.6	69.3	73.9	
5	64.9	72.4	62.8	68.8	

Table 2b. Observed (obs.) and relative (rel.) survival of patients with gastroint. stromal tumor by gender for period 1998-2013 (N=259).






Figure 3a. Relative survival of patients with gastroint. stromal tumor by age category. Included in the evaluation are 259 cases diagnosed between 1998 and 2013.

Age category									
		0-49 yrs		50-59 yrs		60-69	9 yrs	70+	yrs
		n=34		n=48		n=	81	n=	96
	Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
	0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
	1	90.9	90.3	97.9	97.7	86.3	87.1	76.0	80.0
	2	90.9	88.4	91.1	91.8	80.5	82.0	69.2	76.1
	3	82.6	82.6	91.1	90.5	78.8	80.1	63.0	72.2
	4	78.1	75.6	78.4	79.9	77.0	78.9	58.1	71.0
	5	78.1	71.2			67.9	72.3	56.0	69.8

Table 3b. Observed (obs.) and relative (rel.) survival of patients with gastroint. stromal tumor by age category for period 1998-2013 (N=259).






Figure 4a. Relative survival of patients with gastroint. stromal tumor by histology. For 258 of 259 cases diagnosed between 1998 and 2013 valid data could be obtained for this item. Subgroups with sample size <15 are dropped from the chart.

	Hi	stolog	у			
	GI stromal tumor, NOS GI stromal sarcoma					
	n=	n=6 n=252				
Years	obs. %	rel. %	obs. %	rel. %		
0	100.0	100.0	100.0	100.0		
1			86.0	88.2		
2			80.2	83.8		
3			76.2	81.4		
4			70.5	76.9		
5			63.9	71.4		

Table 4b. Observed (obs.) and relative (rel.) survival of patients with gastroint. stromal tumor by histology for period 1998-2013 (N=258).






Figure 4c. Relative survival of patients with gastroint. stromal tumor by extent of disease. For 124 of 259 cases diagnosed between 1998 and 2013 valid data could be obtained for this item. For a total of 87 cases an evaluable classification was established. The grey line represents the subgroup of 172 patients with missing values regarding extent of disease (66.4% of 259 patients, the percent values of all other categories are related to n=87). Subgroups with sample size <15 are dropped from the chart.

Extent of disease									
Local		Local Regional D		Dist	Distant		IOS		
	n=31		n=31 n=4		n=52		n=172		
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	
1	90.3	91.7			76.9	77.5	87.1	89.4	
2	86.2	88.6			64.2	66.9	83.2	86.9	
3	86.2	87.1			59.1	62.6	79.1	84.3	
4					53.3	55.9	74.6	81.2	
5							68.9	77.4	

Table 4d. Observed (obs.) and relative (rel.) survival of patients with gastroint. stromal tumor by extent of disease for period 1998-2013 (N=87).






Figure 5a. Observed post-progression survival of 87 patients with gastroint. stromal tumor diagnosed between 1998 and 2013 (incl. M1). These 87 patients with documented progression events during their course of disease represent 33.6% of the totally 259 evaluated cases. Patients with cancer relapse documented via death certificates only were excluded (n=17, 6.6%).

Medical record documentation often lacks the linguistic severity to distinguish between local relapse, regional lymph node metastasis and distant spread in solid cancers. Frequently, the statement "not specified" is the only information in registries regarding relapse of the disease. The category "All types" denotes all cases who suffered from at least one relapse during the course of disease (incl. primary M1-status). Although, the real number of relapsed patients is likely to be much higher. The accumulated percentage of patients with local relapse or distant metastasis exceeds the 100% value because patients are potientially considered in more than one subgroup.

	Type of ogression	
	All types	
	n=87	
Months	%	
0	100.0	
12	75.6	
24	65.7	
36	58.0	
48	51.1	
60	44.6	

Table 5b. Observed post-progression survival of patients with gastroint. stromal tumor for period 1998-2013 (N=87).

Shortcuts

- MCR Munich Cancer Registry, Germany (Tumorregister München)
- NCI National Cancer Institute, USA
- SEER Surveillance, Epidemiology, and End Results, USA
- UICC Union for International Cancer Control, Geneva
- DCO Death certificate only. The death certificate provides the only notification to the registry.
- NA Not available
- NOS Not otherwise specified
- OS Observed/overall survival (Kaplan-Meier estimate)
- RS Relative survival, compared to the general population, ratio of observed to expected survival (Ederer II method), reflecting excess mortality among cancer patients
- AS Assembled survival chart (observed, expected, relative)
- PPS Post-progression survival, survival since first relapse (Kaplan-Meier estimate) Date of entry: Date of first locoregional recurrence, distant metastasis, unspecified

progression

- Death of all causes
- CS Conditional survival, survival probability under the condition of surviving a given period of time

Recommended Citation

Event:

Munich Cancer Registry. Survival GIST: Gastroint. stromal tumor [Internet]. 2015 [updated 2015 May 13; cited 2015 Jul 1]. Available from: http://www.tumorregister-muenchen.de/en/facts/surv/surv_hGISTE.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

Index of figures and tables

Fig./Tbl	l.	Page
1a	Relative survival by period of diagnosis (chart)	2
1b	Survival by period of diagnosis (table)	2
2a	Survival by gender (chart)	3
2b	Survival by gender (table)	3
3a	Relative survival by age category (chart)	4
3b	Survival by age category (table)	4
4a	Relative survival by histology (chart)	5
4b	Survival by histology (table)	5
4c	Relative survival by extent of disease (chart)	6
4d	Survival by extent of disease (table)	6
5a	Observed post-progression survival (chart)	7
5b	Observed post-progression survival (table)	7